Doctor's Best Immune Support Postbiotic, 500 mg, 60 Veggie Caps

Numerous safety tests have been conducted on EpiCor, revealing an extremely safe profile. Animal studies performed by a leading toxicology laboratory showed no indication of any toxic effects of EpiCor. An acute oral toxicity study on 20 rats showed that the product was safe when given to rats at a single oral dose of 2000 milligrams per kilogram of body weight (equivalent to a human ingesting 280 capsules at once). After 2 weeks the rats showed no clinical symptoms, no deaths, no abnormalities in body weight, and no gross pathological changes. The same safety results were found in a subchronic toxicity study where rats were given up to 1500 milligrams daily for 90 days (equivalent to a human ingesting up to 210 capsules daily for 1.5 years). Again, absolutely no signs or symptoms of toxicity were noted in these animals.

In addition, a standard bacterial reverse mutagenicity test (AMES test) as well as a mammalian cell mutation assay using mouse lymphoma cells revealed no evidence of any increase in mutation rates after exposure to EpiCor. EpiCor also showed no evidence of mitogenicity (inducing increased cell division) in a human lymphocyte proliferation assay. This suggests that EpiCor does not cause over-reactivity of cells.

The effect of EpiCor on specific liver enzymes CYP1A2 and CYP3A4 (enzymes involved in metabolizing certain drugs and other compounds) was assessed. Immortalized hepatocytes (liver cells) were treated with various concentrations of EpiCor and compared to both positive and negative controls. EpiCor did not increase the expression or activity of the liver enzymes, suggesting that it may not affect the metabolism of other substances or medications metabolized by these enzymes if they are taken simultaneously. It also did not appear to be toxic to the cells as measured by lactate dehydrogenase assays and microscopic analysis.

Lastly, EpiCor was tested for safety in humans in an open label study on 15 adult men and women given a single 500 milligram dose for 30 days. On various days throughout the study vital signs were monitored, and blood and urine samples were analyzed. No clinically relevant abnormal effects on the participants were found.

EpiCor also currently has received self-affirmed Generally Regarded as Safe (GRAS) status by an expert panel that included eminent toxicologists.

EpiCor is a novel compound with an incredibly unique composition that has been shown to enhance immune system function.